Company: OPGN
Filing Date: 2025-10-31
Form Type: 10-Q
Source: 0001829126-25-008771
Chunk: 91

Company: OPGEN INC
Filing Date: 2025-10-31
Form: 10-Q
Item: Part I, Item 2
Chunk 91
---
,000,000

    $
    196,149

We recognized revenue in the six months ended
June 30, 2025 solely related to our single contract to provide listing sponsorship and consulting services, as CapForce completed the
second performance obligation within the Engagement Agreement, earning proceeds of $4.0 million in the Client’s equity. We did not
generate any product sales or laboratory services revenue in the six months ended June 30, 2025, due to the winding down of our legacy
precision medicine business and repositioning ourselves in the financial services and technology industry.

Operating
expenses

    Six Months Ended
        June 30,

    2025

    2024

    Cost of products sold
     
    $
    -

    $
    31,636

    Cost of services

    -

    1,575

    Research and development

    -

    48,820

    General and administrative

    1,108,182

    3,252,770

    Sales and marketing

    11,889

    153,973

    Total operating expenses
     
    $
    1,120,071

    $
    3,488,774

Our
total operating expenses for the six months ended June 30, 2025 decreased approximately 68% when compared to the same period in 2024.
Operating expenses changed as follows:

    ●
    Cost
        of products sold: cost of products sold for the six months ended June 30, 2025 decreased 100% when compared to the same period in
        2024. The decrease in cost of products sold aligns with the decrease in product sales in the first half of 2025, which is due to the Company
        scaling down its legacy operations and repositioning its business; 

    ●
    Cost
        of services: cost of services for the six months ended June 30, 2025 decreased 100% when compared to the same period in 2024. The
        decrease in cost of services aligns with the decrease in laboratory services in the first half of 2025, which is due to the Company scaling
        down its legacy operations and repositioning its business; and 

    ●
    Research
        and development, general and administrative, and sales and marketing: research and development, general and administrative, and sales
        and marketing expenses decreased approximately 100%, 66